Alternative Health Grants Reviewed: Pain Relief Ideas in Hiding
Published Date: 3/26/2025
Notice
Summary
The National Center for Complementary and Integrative Health is holding a closed virtual meeting from April 21-23, 2025, to review special grant applications focused on pain management research. This meeting affects researchers applying for funding and keeps sensitive info private. No money changes now, but decisions could impact future research funding.
Analyzed Economic Effects
2 provisions identified: 1 benefits, 0 costs, 1 mixed.
Your HEAL grant reviewed April 21-23
If you are a researcher applying for the HEAL Initiative (NIH–DOD–VA) Pain Management Collaboratory UG3/UH3 clinical trial demonstration project grants, your application will be reviewed in a closed virtual meeting on April 21–23, 2025. The panel’s agenda is to review and evaluate grant applications for those demonstration projects.
Applicant trade secrets and privacy protected
The meeting will be closed to the public under 5 U.S.C. 552b(c)(4) and 552b(c)(6) to protect confidential trade secrets, commercial property (such as patentable material), and personal information tied to the grant applications. If you submitted an application, that confidential information will not be publicly disclosed during this review.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-17687, Center for Scientific Review; Notice of Closed Meetings
The Center for Scientific Review at the NIH is holding several closed virtual meetings in October 2026 to review and evaluate grant applications. These meetings protect private info and trade secrets, ensuring fair and confidential decisions. Scientists applying for grants in genetics, molecular sciences, oral health, and cancer research are the ones affected, with no direct cost changes announced.
2026-17438, Center For Scientific Review; Notice of Closed Meetings
The NIH's Center for Scientific Review is holding several closed virtual meetings in late September 2026 to review and evaluate grant applications. These meetings protect private info and trade secrets, affecting researchers applying for funding. No direct money changes are announced, but these reviews decide who gets research grants.
2026-16683, Proposed Collection; 60-Day Comment Request; Data Use Certification for the NIH National Institute on Drug Abuse Data Share Site
The purpose of this notice is to inform the public of the information collection requirement for the NIDA Data Share, the data use terms and conditions, and to request a progress report statement at the time of renewal. In compliance with the requirement of the Paperwork Reduction Act of 1995 to provide opportunity for public comment on proposed data collection projects, the National Institute on Drug Abuse (NIDA) will publish periodic summaries of proposed projects to be submitted to the Office of Management and Budget (OMB) for review and approval.
2026-16544, Government-Owned Inventions; Availability for Licensing
The inventions listed below are owned by an agency of the U.S. Government and are available for licensing to achieve expeditious commercialization of results of federally-funded research for the benefit of the public health.
2026-16440, NIH Owned Invention Available for License: Soluble Tissue Factor, a Novel Target, and Antibodies, for Diagnosis, Prevention and Treatment of Thrombosis and Related Conditions
Scientists at the National Cancer Institute (NCI) have discovered a novel therapeutic, diagnostic and prognostic target for thrombosis: Soluble Tissue Factor (sTF). NCI has generated first-in- class antibodies and platform selectively neutralizing pathological coagulation while preserving normal hemostasis. This platform technology can be used to prevent, diagnose and treat pathological thrombosis caused by a variety of clinical conditions-including cancer, sepsis, infectious diseases (e.g., COVID), autoimmune disorders, trauma, heart conditions and inflammatory conditions. It offers a much more sensitive and specific test of thrombosis than the current D-dimer test. It may be applicable to any clinical condition which induces necroptosis, pyroptosis and NETtosis, such as cancer, neurodegenerative disease, ischemia-reperfusion and acute injuries, traumatic injuries, bacterial and viral infections, cardiovascular conditions, and atherosclerosis, inflammatory, autoimmune conditions, and others.
2026-16071, Proposed Collection; 60-Day Comment Request: The Impact of Clinical Research Training and Medical Education at the Clinical Center on Physician Careers in Academia and Clinical Research (Clinical Center)
In compliance with the requirement of the Paperwork Reduction Act of 1995, for opportunity for public comment on proposed data collection projects, the Clinical Center, the National Institutes of Health (NIH) will publish periodic summaries of proposed projects to be submitted to the Office of Management and Budget (OMB) for review and approval.
Previous / Next Documents
Previous: 2025-05068, National Institute of Diabetes and Digestive and Kidney Diseases; Notice of Closed Meeting
The National Institute of Diabetes and Digestive and Kidney Diseases is holding a closed virtual meeting on April 11, 2025, to review and decide on grant applications. This meeting affects researchers seeking funding for diabetes, digestive, and kidney disease studies. The discussions are private to protect sensitive information and personal privacy, ensuring fair and secure grant decisions.
Next: 2025-05070, National Institute of Diabetes and Digestive and Kidney Diseases; Notice of Closed Meeting
The National Institute of Diabetes and Digestive and Kidney Diseases is holding a closed virtual meeting on May 2, 2025, to review special grant applications focused on diabetes research. This meeting affects researchers seeking funding and keeps sensitive info private. No money changes are announced, but the grant review could impact future research funding decisions.